Latest Content

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings.

The FDA has approved ziftomenib for relapsed or refractory acute myeloid leukemia harboring NPM1 mutations with no alternative treatment options.

Kristi Orbaugh, MSN, RNP, AOCN, AOCNP, shared the key toxicities of each CDK4/6 inhibitor and how to monitor for them.

Care at every step is the ethical duty of nurses, says Katherine Brown-Saltzman, MA, RN, in this episode of Onc Nurse On Call.

After undergoing EBRT and brachytherapy at 14, an AYA cancer survivor discusses her experience with a rare vaginal cancer and Turner syndrome.

Catherine Boyles, RN, OCN, explains how to help patients help themselves when preparing for appointments.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, explains that later cytopenias should be monitored in patients undergoing CAR T-cell therapy.

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj for use in patients with high-risk smoldering multiple myeloma.

The frontline addition of cancer vaccine IO102-IO103 to pembrolizumab demonstrated an increase in PFS in patients with advanced melanoma.

Daniel Glidden, MS, PA-C, discusses key data oncology APPs should be aware of and how to start incorporating exercise in cancer care.

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data.